Stock Price Falls to Three-Year Low, Kailay Medical Launches Buyback Plan

GateUser-bd883c58 · 2026-03-25T20:00:52+00:00

Kaili Medical announced a share repurchase plan of 100 million to 200 million yuan aimed at enhancing shareholder value. However, the company's performance has continued to decline, with net profits dropping significantly and the stock price performing poorly. Before the buyback, executives had already increased their holdings, reflecting an intrinsic connection.

GateUser-bd883c58

2026-03-25 20:00:52

Abstract generation in progress

What is the intrinsic connection between AI, executive shareholding increases, and buyback plans?

Reporter: Yan Fengfeng Editor: Wu Yongjiu

On March 17, KaiLi Medical announced a buyback plan of 100 million to 200 million yuan, intending to use its own or raised funds to repurchase A-shares through centralized bidding transactions. The buyback price will not exceed 40.32 yuan per share, with an expected repurchase ratio of 0.57% to 1.15%. The repurchased shares will all be canceled to reduce registered capital. Before the company announced the buyback, some executives had already increased their holdings.

The company’s weak stock performance and poor financial results are key factors. Over the past two years, net profit has continued to decline significantly. In 2024, the company achieved operating revenue of 2.014 billion yuan, down 5.02% year-on-year; net profit attributable to the parent was 142 million yuan, a sharp decrease of 68.67% year-on-year. Entering 2025, the company’s performance continues to decline sharply. In the first three quarters of 2025, revenue reached 1.459 billion yuan, up 4.37% year-on-year; but net profit attributable to the parent was only 33.51 million yuan, down 69.25% year-on-year.

See the full article: Stock price hits three-year low, KaiLi Medical launches buyback plan, doubts over achieving equity incentive goals amid high costs

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.